Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have been assigned an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $78.00.

Several analysts have weighed in on the stock. The Goldman Sachs Group reaffirmed a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a research note on Tuesday. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research note on Tuesday. HC Wainwright upped their price objective on shares of Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research note on Wednesday, March 11th. Finally, William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday.

Vera Therapeutics Stock Performance

NASDAQ VERA opened at $33.38 on Friday. The stock has a market cap of $2.40 billion, a P/E ratio of -6.03 and a beta of 0.93. The company’s 50-day simple moving average is $37.87 and its 200 day simple moving average is $41.31. Vera Therapeutics has a twelve month low of $19.07 and a twelve month high of $56.05. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter last year, the company earned ($0.81) EPS. As a group, research analysts forecast that Vera Therapeutics will post -6.17 earnings per share for the current fiscal year.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $36.74, for a total transaction of $679,690.00. Following the sale, the chief executive officer directly owned 216,744 shares of the company’s stock, valued at $7,963,174.56. This represents a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by company insiders.

Institutional Trading of Vera Therapeutics

Several hedge funds have recently modified their holdings of VERA. GAMMA Investing LLC lifted its stake in Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after acquiring an additional 236 shares during the last quarter. Optimize Financial Inc lifted its stake in Vera Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after acquiring an additional 256 shares during the last quarter. Virtus Investment Advisers LLC lifted its stake in Vera Therapeutics by 5.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock valued at $271,000 after acquiring an additional 290 shares during the last quarter. Intech Investment Management LLC lifted its stake in Vera Therapeutics by 2.4% in the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock valued at $903,000 after acquiring an additional 424 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in Vera Therapeutics by 2.0% in the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after acquiring an additional 550 shares during the last quarter. 99.21% of the stock is owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.